12:00 PM EDT, 07/07/2025 (MT Newswires) -- GSK (GSK) said Monday it completed its acquisition of Boston Pharmaceuticals' steatotic liver disease therapeutic candidate efimosfermin.

As part of the deal that was first announced in May, GSK has acquired Boston Pharmaceuticals' BP Asset IX subsidiary for an upfront payment of $1.2 billion and up to $800 million in success-based milestone payments. The drugmaker also said it will be responsible to provide Novartis ( NVS ) with milestone payments as well as royalties relating to efimosfermin.

Efimosfermin is a once-monthly fibroblast growth factor 21 analog in development for metabolic dysfunction-associated steatohepatitis and alcohol-related liver disease, GSK said.

GSK said the drug's antifibrotic mechanism may make it suitable for more advanced stages of liver disease and sees future combination potential with its GSK'990 therapeutic.

Price: 38.32, Change: +0.14, Percent Change: +0.37